Darrah Wong
Optometrist · Waipahu, HINPI 1841411915
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 236 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations.
Across 236 payments — averaging $20.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$884
- Novartis$702
- AbbVie$586
- Alcon$433
- Aerie Pharmaceuticals, Inc.$402
- Bausch & Lomb Americas Inc.$400
- plus $1K from 10 others
What the payments were for
- Food & beverage$4,815100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 34 | $884 |
| Novartis | 48 | $702 |
| AbbVie(2 entities) | 24 | $586 |
| Alcon | 19 | $433 |
| Aerie Pharmaceuticals, Inc. | 22 | $402 |
| Bausch & Lomb Americas Inc. | 21 | $400 |
| Amgen(2 entities) | 19 | $382 |
| Oyster Point Pharma, Inc. | 10 | $233 |
| Kala Pharmaceuticals, Inc. | 11 | $187 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $185 |
| Tarsus Pharmaceuticals, Inc. | 7 | $157 |
| Genentech USA, Inc. | 4 | $89 |
| Shire North American Group Inc | 4 | $75 |
| ANI Pharmaceuticals, Inc. | 1 | $35 |
| Dompe US, Inc. | 1 | $32 |
| Astellas Pharma US Inc | 1 | $32 |
How this compares
$4,815 in reported general payments places this provider in the 85th percentile of 310 optometrist providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 202 | $265,003 |
| XiidraLifitegrast | 127 | $178,001 |
| RocklatanNetarsudil Mesylat/Latanoprost | 110 | $48,257 |
| CequaCyclosporine | 34 | $31,858 |
| VyzultaLatanoprostene Bunod | 62 | $27,419 |
| Alphagan PBrimonidine Tartrate | 43 | $20,876 |
| Restasis MultidoseCyclosporine | 23 | $20,185 |
| Brimonidine Tartrate | 86 | $15,372 |
| LumiganBimatoprost | 24 | $14,705 |
| MieboPerfluorohexyloctane/Pf | 14 | $10,775 |
| CombiganBrimonidine Tartrate/Timolol | 29 | $10,163 |
| TyrvayaVarenicline Tartrate | 15 | $10,057 |
| ProlensaBromfenac Sodium | 24 | $8,703 |
| Cyclosporine | 16 | $6,659 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 27 | $6,340 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Alphagan P, Restasis Multidose, Lumigan, Combigan | $586 | $330,932321 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $400 | $216,195203 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $402 | $48,257110 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $884 | $31,85834 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $233 | $10,05715 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $185 | $8,70324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 310 optometrist providers in Hawaii.
Other optometrist in Waipahu
- Jon IshiharaWaipahu$13K
- Kathy IshimotoWaipahu$8K
- Camie Nakagawa-KakudaWaipahu$7K
- Linda ArakakiWaipahu$6K
- Natalie RamirezWaipahu$4K
- Grant MiyashiroHilo$26K
- Jana SouzaHilo$16K
- Geoffrey ReynoldsMililani$14K
- Patricia IchimuraHonolulu$11K
- Lillian TakamuraHonolulu$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.